• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection and Management in Pharmacovigilance
  • News
  • Opinion
  • About
  • Glossary

Sources of data

Sources of data for PV analytics

Following is a non-exhaustive list of sources of data and information to be used in the framework of PV analytics.

Adverse event (AE) / adverse drug reaction (ADR) case reports

  • Company reports of AEs / ADRs generated during the entire life cycle of the medicinal product, which includes clinical development and post-market.
  • Health Agency databases: FAERS, EudraVigilance, Vigibase.

Studies

  • Nonclinical studies
  • Clinical trials, including research in unapproved populations or indications
  • Observational studies, real world data, registries
  • Systematic reviews and meta-analyses
  • Outcomes research studies
  • Comparative effectiveness research
  • Comparative safety research
  • Health economics analyses

Scientific literature

  • Published scientific literature or reports from abstracts, including information presented at scientific meetings
  • Unpublished manuscripts

Active surveillance systems

  • Sentinel systems or sentinel sites

Market access – market research

  • Product usage data and drug use information
  • Patient support programs

Healthcare – related data

  • Administrative and claims data from health insurers
  • Clinical data, including vital signs and laboratory test results
  • Electronic health records, electronic medical records
  • Hospital data
  • Medicare data

Internet

  • Marketing authorization holder-sponsored websites
  • Internet search engines
  • Patient forums
  • Social media channels

Other

  • Information arising from licensing partners, other sponsors, or academic institutions / research networks
  • Product quality investigations
  • Information from regulatory authorities
  • Information obtained from wearables
  • Ad-hoc reports generated by company field teams, and medical requests of information regarding potential benefits or risks
Related Terms:
  • Term: Adverse Event (AE)
  • Term: Adverse Drug Reaction (ADR)
  • Term: Active Surveillance
  • Term: Claims Data

Primary Sidebar

Subscribe in a reader

Search Website

Uses of Generative AI in Pharmacovigilance

Featured News / Posts

Signal Analytics Technology in Pharmacovigilance

Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

Pharmacovigilance plays a crucial role in ensuring public safety by monitoring, … [Read More...] about Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

8 Common FDA Applications for Drugs & Biologics

The U.S. Food and Drug Administration (FDA) has several types of applications … [Read More...] about 8 Common FDA Applications for Drugs & Biologics

Key IND Enabling Studies: Navigating Preclinical Development Regulations

Investigational New Drug (IND) applications represent a critical stage in the … [Read More...] about Key IND Enabling Studies: Navigating Preclinical Development Regulations

Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Pharmacokinetics and pharmacodynamics are two fundamental pillars in the field … [Read More...] about Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Regulatory authorities in the pharmaceutical industry have established standards … [Read More...] about Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

In the realm of patient safety and pharmacovigilance, statistical signal … [Read More...] about Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

Pharmacovigilance signal detection software plays a crucial role in … [Read More...] about Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

A Periodic Benefit-Risk Evaluation Report (PBRER) serves as a structured … [Read More...] about What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Drug safety and pharmacovigilance are crucial aspects of public … [Read More...] about Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

he Development Safety Update Report (DSUR) is a crucial document that serves as … [Read More...] about Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

  • What is a DSUR (Development Safety Update Report)? An Essential Guide for Clinical Research
  • What is a BLA (Biologics License Application)? Essential Guide for Professionals
  • What is a PADER? – Periodic Adverse Drug Experience Report Explained

RSS ICH News

  • An error has occurred, which probably means the feed is down. Try again later.

RSS From Nature journal

  • A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development
  • Description of barriers to the deprescription of inappropriate drugs in French hospitalized geriatric services
  • The association between antenatal indomethacin exposure and persistent pulmonary hypertension of the newborn in extremely preterm infants
  • Synergistic effect of synthetic derivatives of 1,3,4-thiadiazole with amphotericin B in antifungal therapy
  • A pharmacovigilance analysis of post-marketing safety of durvalumab

Copyright © 2025 · News Pro on Genesis Framework · WordPress · Log in